KRRO stock forecast, quote, news & analysis
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases... Show more
Why Korro Bio (KRRO) Stock Is Up +40% in the Last 30 Days
Key Takeaways
- Korro Bio (KRRO) shares climbed roughly +40% over the trailing 30 days, rebounding from about $9.57 to above $13.40.
- The rally was driven primarily by positive preclinical data for KRRO-111, its RNA-editing candidate for alpha-1 antitrypsin deficiency (AATD), announced on October 22, 2026.
- Over the trailing quarter, the stock was volatile, sliding into the low-to-mid single digits before the data readout triggered a sharp recovery.
- Analyst sentiment remains broadly positive, with a consensus Strong Buy rating and price targets that sit well above the recent share price.
- Investors continue to follow pipeline progress across KRRO-110, KRRO-111, and KRRO-121, along with regulatory and clinical milestones expected into 2027.
- For additional detail on valuation and forward expectations, explore the company's Price Targets, Earnings, and Forecast pages.
- To see how automated strategies are positioned across the market, explore Trending AI Robots.
Korro Bio (KRRO) Company Overview and Market Position
Korro Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing a new class of genetic medicines using RNA editing. The company's proprietary OPERA® (Oligonucleotide Promoted Editing of RNA) platform leverages the body's natural adenosine deaminase acting on RNA (ADAR) enzymes to make precise, transient single-base edits to messenger RNA rather than DNA. This approach is designed to restore or create functional proteins with enhanced activity while offering greater precision and tunability compared with traditional DNA-editing methods.
Korro's pipeline includes KRRO-110 and KRRO-111, both in development for alpha-1 antitrypsin deficiency (AATD), and KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide being studied for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy. As a pre-commercial company, Korro generates minimal revenue and relies on a differentiated platform, early clinical data, and a strong cash position to attract investor interest. Its shares carry above-average volatility, reflecting the binary, news-driven nature of biotech development.
Korro Bio (KRRO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, KRRO rose from a closing price of approximately $9.57 in late September to above $13.40, a gain of roughly 40%. The move was not linear: shares drifted lower through much of September and early October before surging more than 29% in a single session on October 22, 2026, following the company's KRRO-111 preclinical data release.
The trailing quarter tells a broader story of volatility. From levels near $13 in late August, the stock fell to a low around $8.81 in mid-October before the data-driven recovery pushed it back above $13. The net change over the quarter was therefore modest, but the path was marked by sharp drawdowns and rapid rebounds, consistent with the stock's high-beta profile and the event-driven nature of its clinical pipeline.
What Drove KRRO Stock Price in the Last 30 Days
The dominant catalyst was the October 22, 2026 announcement of preclinical results for KRRO-111. Korro reported that the candidate achieved greater than 95% SERPINA1 mRNA editing in repeat-dose mouse studies, restored circulating functional M-AAT, increased total AAT by approximately six-fold, and reduced pathogenic hepatic Z-AAT by up to 95%. The company positioned the data as best-in-class and said a regulatory submission is expected in the first half of 2027.
Supportive analyst activity reinforced the move. Around the data readout, H.C. Wainwright reiterated a Buy rating with a $15 price target, while earlier in October Oppenheimer reaffirmed Buy with a $22 target and Piper Sandler maintained Buy with a $30 target. Insider and institutional buying added to the positive tone, with major shareholder Lynx1 Capital Management LP reporting purchases totaling approximately $885,000 in late October. These factors, combined with progress on the KRRO-121 Phase 1/2 ANCHOR trial, contributed to the sharp rebound in sentiment.
What Drove KRRO Stock Performance Over the Last Quarter
The quarterly narrative centered on pipeline execution across three programs. In August, Korro submitted an application to Australian regulators to begin a first-in-human Phase 1/2 trial for KRRO-121, and by early October the company announced the first participants had been dosed. In late September, Korro disclosed a regulatory filing to initiate a first-in-human study for KRRO-110 in AATD. These milestones were offset at times by broader risk-off sentiment in high-beta biotech names, which contributed to the stock's mid-quarter weakness before the KRRO-111 data release reversed the trend. The combination of steady clinical advancement, analyst support, and a decisive positive data event shaped the stock's multi-month round-trip.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies from a broader universe of hundreds of AI-driven bots that trade thousands of tickers. Only top-performing and most relevant bots appear in this section, which can make it a useful starting point for traders exploring systematic approaches. The bots vary in strategy, timeframe, and performance metrics, so the page offers exposure to different styles rather than a single model. For those interested in how AI-powered tools approach names like KRRO and the wider market, the Trending AI Robots page is worth exploring.
KRRO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on clinical and regulatory milestones. The expected regulatory submission for KRRO-111 in the first half of 2027 is a key catalyst, as is the continued progress of the KRRO-121 Phase 1/2 ANCHOR trial and the KRRO-110 first-in-human program. Upcoming quarterly results will be watched for operating-expense trends, cash runway commentary, and any guidance updates. As a clinical-stage company, Korro remains sensitive to trial outcomes, regulatory decisions, and shifts in risk appetite across the biotechnology sector. Analyst price targets and ratings revisions may also influence near-term sentiment, though the primary long-term drivers remain data readouts and pipeline execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KRRO in upward trend: 10-day moving average broke above 50-day moving average on October 30, 2026
The 10-day moving average for KRRO crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on KRRO as a result. In 70 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for KRRO just turned positive on October 20, 2026. Looking at past instances where KRRO's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.
KRRO moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 226 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KRRO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KRRO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.371) is normal, around the industry mean (3.051). P/E Ratio (-1.682) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology